ciltacabtagene autoleucel
janssen
['multiple myeloma', '4133', 'cartitude-2', 'cilta-cel', 'ct041', 'mmsm']
in patients with progressive multiple myeloma after 1 to 3 prior lines of therapy, a single cilta-cel infusion led to deepening and durable responses at 17.1 months in the cartitude-2 study (nct04133636). #asco22 #mmsm 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.